BACKGROUND: Investigation of the rate of active conversion of flucytosine to fluorouracil by microorganisms in the intestinal microflora. METHODS: Active conversion of flucytosine was investigated using viable and nonviable Escherichia coli at different flucytosine concentrations. Additionally, flucytosine conversion was studied in fecal specimens from 3 neutropenic patients at the start of the antimicrobial/antifungal prophylaxis (C/A regimen) and 1 week later. RESULTS: Flucytosine levels decreased by an average of 72, 71 and 72% flucytosine after incubation for 48 h of 10(10) viable E. coli /ml suspension in broth containing 13, 130 and 1300 mg/l flucytosine, respectively. The decreasing flucytosine levels corresponded approximately to an identical increase in fluorouracil levels. Also, a 44% decrease of flucytosine levels occurred when nonviable E. coli were used, indicating that bacterial viability is not necessary for this conversion. When fecal specimens of 2 patients were investigated prior to the C/A regimen, significant flucytosine conversion occurred, whereas this conversion was not observed in the corresponding fecal specimens after 1 week of C/A regimen. CONCLUSION: These in vitro experiments showed that extensive flucytosine conversion can occur in the human intestinal microflora by E. coli. Consequently, fluorouracil exposure and fluorouracil-related toxicity may occur in the flucytosine-treated patient. Copyright 2003 S. Karger AG, Basel
BACKGROUND: Investigation of the rate of active conversion of flucytosine to fluorouracil by microorganisms in the intestinal microflora. METHODS: Active conversion of flucytosine was investigated using viable and nonviable Escherichia coli at different flucytosine concentrations. Additionally, flucytosine conversion was studied in fecal specimens from 3 neutropenicpatients at the start of the antimicrobial/antifungal prophylaxis (C/A regimen) and 1 week later. RESULTS:Flucytosine levels decreased by an average of 72, 71 and 72% flucytosine after incubation for 48 h of 10(10) viable E. coli /ml suspension in broth containing 13, 130 and 1300 mg/l flucytosine, respectively. The decreasing flucytosine levels corresponded approximately to an identical increase in fluorouracil levels. Also, a 44% decrease of flucytosine levels occurred when nonviable E. coli were used, indicating that bacterial viability is not necessary for this conversion. When fecal specimens of 2 patients were investigated prior to the C/A regimen, significant flucytosine conversion occurred, whereas this conversion was not observed in the corresponding fecal specimens after 1 week of C/A regimen. CONCLUSION: These in vitro experiments showed that extensive flucytosine conversion can occur in the human intestinal microflora by E. coli. Consequently, fluorouracil exposure and fluorouracil-related toxicity may occur in the flucytosine-treated patient. Copyright 2003 S. Karger AG, Basel
Authors: Annemarie E Brouwer; Hendrikus J M van Kan; Elizabeth Johnson; Adul Rajanuwong; Prapit Teparrukkul; Vannaporn Wuthiekanun; Wirongrong Chierakul; Nick Day; Thomas S Harrison Journal: Antimicrob Agents Chemother Date: 2006-12-28 Impact factor: 5.191
Authors: R Aarnoutse; J M P G M de Vos-Geelen; J Penders; E G Boerma; F A R M Warmerdam; B Goorts; S W M Olde Damink; Z Soons; S S M Rensen; M L Smidt Journal: Int J Colorectal Dis Date: 2017-04-25 Impact factor: 2.571
Authors: Jérémy Béguin; Virginie Nourtier; Murielle Gantzer; Sandrine Cochin; Johann Foloppe; Jean-Marc Balloul; Eve Laloy; Dominique Tierny; Bernard Klonjkowski; Eric Quemeneur; Christelle Maurey; Philippe Erbs Journal: BMC Vet Res Date: 2020-08-25 Impact factor: 2.741
Authors: Jesse C Nussbaum; Arthur Jackson; Dan Namarika; Jacob Phulusa; Jullita Kenala; Creto Kanyemba; Joseph N Jarvis; Shabbar Jaffar; Mina C Hosseinipour; Deborah Kamwendo; Charles M van der Horst; Thomas S Harrison Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079